## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.23 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($119.04)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Dir Kramer Sells 5,611 ($713.2K) Of Gilead Sciences Inc [GILD]**
- Source: TradingView | 20251201T215356 | Somewhat-Bearish | Relevance: 100%
- Refinitiv reports that Kelly A. Kramer, a Director of Gilead Sciences Inc [GILD], sold 5,611 shares through planned transactions between November 26-28, 2025, totaling $713,186. These transactions included both an exercise of shares at $81.00 and a subsequent sale at $127.11 per share. The sales were executed under a prearranged trading plan (10b5-1).

**2. Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251203T101843 | Somewhat-Bullish | Relevance: 100%
- Invesco Ltd. increased its holdings in Gilead Sciences, Inc. by 33.5% in the second quarter, acquiring an additional 3,394,330 shares. This purchase brings Invesco's total ownership to 13,521,228 shares, valued at approximately $1.5 billion, and represents 1.09% of the biopharmaceutical company. The article also details significant buying and selling activity by other institutional investors and company insiders, alongside recent analyst ratings and financial performance data for Gilead Sciences.

**3. Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock**
- Source: MarketBeat | 20251202T232225 | Somewhat-Bullish | Relevance: 100%
- Gilead Sciences CEO Daniel Patrick O'day sold 10,000 shares of company stock for $1,265,400 on November 28, reducing his stake by 1.72%. This follows similar sales in October and September, indicating a pattern of insider selling. The company recently reported beating Q3 earnings and revenue estimates and declared a quarterly dividend.

**4. Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock**
- Source: MarketBeat | 20251202T225530 | Somewhat-Bullish | Relevance: 100%
- Gilead Sciences Director Kelly Kramer sold 2,806 shares of GILD stock for $356,670.66, reducing her stake by 67.7%. The sale occurred amidst strong quarterly earnings that surpassed expectations, and the company issued optimistic FY2025 guidance. Analysts maintain a "Moderate Buy" rating with an average target price above the current trading level.

**5. Gilead Sciences (NASDAQ:GILD) Director Sells $356,515.50 in Stock**
- Source: MarketBeat | 20251202T225530 | Somewhat-Bullish | Relevance: 100%
- Gilead Sciences director Kelly Kramer sold 2,805 shares of the company's stock for a total of $356,515.50, significantly reducing her position. This transaction follows a strong quarter where Gilead beat EPS and revenue expectations and provided optimistic FY2025 guidance. The company also announced a quarterly dividend and analysts maintain a "Moderate Buy" rating with a consensus target price of $130.65.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |
| 2025-11-03 | Truist Securiti | $145 | $127 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |
| 2025-11-03 | Truist Securiti | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($10.00M) |
| Sells | 13 ($5.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.9M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.23 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $154.7B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.23 |
| Forward P/E | 14.3 |
| Current P/E | 15.3 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.3% to -1.5% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.47% (CS: 37) | Neutral |
| RSI_14 | 54.0 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $125.00
- **Stop Loss:** $119.04 (4.8% risk)
- **Target:** $136.92 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 159
- **Position Value:** $19,875.00
- **Portfolio %:** 19.88%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*